Sight Sciences Announces TearCare System Recognition in TFOS DEWS III Guidelines

Sight Sciences' TearCare System has been recognized in the TFOS DEWS III report, a widely recognized standard in dry eye disease management. The system's clinical efficacy is highlighted in multiple published studies, including the SAHARA and OLYMPIA randomized controlled trials. The report validates TearCare's integral role in patient care and solidifies its position alongside recognized technologies in ocular surface disease.

Sight Sciences Inc. (NASDAQ: SGHT) has announced that its TearCare System has been included in the TFOS DEWS III report, a widely recognized standard in dry eye disease management. The inclusion signifies significant validation for TearCare's clinical efficacy in treating dry eye disease (DED) and meibomian gland disease (MGD).

The DEWS III report, published in the American Journal of Ophthalmology, highlights multiple clinical studies supporting TearCare's effectiveness. The SAHARA trial demonstrated clinical superiority over Restasis in improving Tear Breakup Time and gland function, while the OLYMPIA trial showed significant improvement in DED symptoms, particularly in severe cases compared to LipiFlow.

Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences, stated, "For the first time, TearCare has been officially included in the TFOS DEWS III Management and Therapy Report. This powerful third-party validation highlights TearCare’s clinical relevance in treating meibomian gland disease (MGD) and solidifies our position alongside the most recognized technologies in ocular surface disease."

The recognition of the TearCare System as an interventional procedure within the DEWS III report underscores its clinical efficacy and integral role in patient care. The report itself is highly influential for clinicians refining treatment algorithms for dry eye.

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative, interventional solutions intended to transform care and improve patients’ lives. The TearCare System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD).

References:
[1] https://www.stocktitan.net/news/SGHT/sight-sciences-announces-recognition-of-the-tear-care-system-in-tfos-706yz1hgj3hy.html